Právní předpis byl sestaven k datu 19.12.2013.
Zobrazené znění právního předpisu je účinné od 25.12.2012 do 19.12.2013.
97
XXXXXXX
Xxxxxxxxxxxx zahraničních xxxx,
xxxxxx se xxxx x doplňuje sdělení Xxxxxxxxxxxx xxxxxxxxxxxx věcí x. 58/2007 Xx. x. x., x. 46/2008 Sb. x. x. x x. 47/2012 Xx. x. x. x Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx dne 16. listopadu 2011 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx schválení xxxxxx xxxxx Xxxxxxx X - Seznamu xxxxxxxxxx xxxxx x xxxxx - Mezinárodní xxxxxxxx Mezinárodní xxxxxx xxxxx dopingu xx xxxxxx.1)
S novým xxxxxx Xxxxxxx I xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx.
Xxxx xxxxx Xxxxxxx I xxxxxxxxx x xxxxxxxx x xxxxxxx s xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. ledna 2012 x xxxxx xxxx xxxxxxxxx x xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Dnem vstupu xxxxxx xxxxx Xxxxxxx X x xxxxxxxx xxxxxxxx platit xxxxx Xxxxxxx I Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx xxxxxx xx 1. ledna 2011 x xxxxxxxxx xxx č. 47/2012 Sb. m. s.
Anglické xxxxx Xxxxxxx X x xxxx překlad xx xxxxxxx xxxxxx xx vyhlašují současně.
1) Mezinárodní xxxxxx proti xxxxxxx xx sportu přijatá xxx 19. xxxxx 2005 x Paříži xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s.
MEZINÁRODNÍ XXXXXX XXXXX XXXXXXX XX XXXXXX
Příloha X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx
Paříž, 1. xxxxx 2012
XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX XXX 2012
SVĚTOVÝ XXXXXXXXXXXXX XXXXX
Platný xx 1. xxxxx 2012
Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx xxxxxx X1, X2, X4.4, X4.5 x X6(x) a Zakázaných xxxxx X1, X2 x M3.
XXXXX X XXXXXX XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX SOUTĚŽ) |
XXXXXXXX XXXXX
X0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx látka, xxxxx xxxx xxxxxxxx v xxxxxxxxxxxxx xxxxxxx Seznamu x xxxx xxxxxxxx xxxxxxxxx pro xxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx zdravotnickým regulačním xxxxxx (např. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx po xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx xxxx), je xxxxxxxx xxxxx.
S1. XXXXXXXXXX XXXXX
Anabolické xxxxx jsou xxxxxxxx.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):
(x) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-androst-1-en-3β,17β-diol); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); drostanolon; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); fluoxymesteron; xxxxxxxxxx; xxxxxxxxx (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan); gestrinon; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-hydroxy-17α-methyl-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-dion); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; oxandrolon; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-5α-androstano [3,2-x]xxxxxxx); xxxxxxxxx; stanozolol; xxxxxxxxx; 1-xxxxxxxxxxx (17β-hydroxy-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** XXX, pokud xxxx xxxxxx xxxxxxxx:
Xxxxxxxxxxxxx (androst-5-en-3β,17β-diol), androstendion (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX), xxxxxxxxxxx x xxxxxx metabolity x xxxxxxx, xxx xx s omezením xxxxx xx ně:
5α-xxxxxxxxx-3α,17α-xxxx | 5-androstendion (xxxxxxx-5-xx-3,17-xxxx) |
5α-xxxxxxxxx-3α,17β-xxxx | |
5α-xxxxxxxxx-3β,17α-xxxx | xxx-xxxxxxxxxxxxxxxxxx |
5α-xxxxxxxxx-3β,17β-xxxx | xxxxxxxxxxxxxx |
xxxxxxx-4-xx-3α,17α-xxxx | 3α-hydroxy-5αandrostan-17-on |
xxxxxxx-4-xx-3α,17β-xxxx | 3β-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-5-xx-3β,17α-xxxx | 7α-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17α-xxxx | 7β-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17β-xxxX | 7-xxxx-XXXX |
xxxxxxx-5-xx-3β,17α-xxxx | 19-xxxxxxxxxxxxxx |
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx) | 19-xxxxxxxxxxxxxxxxx |
2. Xxxxxxx anabolické xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), tibolon, xxxxxxx, xxxxxxxxxx, ale xx s omezením xxxxx na xx.
Xxx xxxxx xxxxxxx xxxx sekce: * "xxxxxxxx" xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxx xxxxxxxx xxxxxxx produkovat xxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx x xxxxx, kterou xxxx xxxx produkovat xxxxxxxxx. |
X2. XXXXXXXXX XXXXXXX, RŮSTOVÉ XXXXXXX X PŘÍBUZNÉ XXXXX
Xxxxxxxxxxx látky x xxxxxx xxxxxxxxxx xxxxxxx xxxx zakázány:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. erytropoetin (XXX), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), xxxxxxxxxxx /Xxxxxxxx/);
2. Choriogonadotropin (XX) x Xxxxxxxxxxxx hormon (XX) x xxxx;
3. Xxxxxxxx;
4. Xxxxxxxxxxxxxx;
5. Růstový xxxxxx (GH), fibroblastové xxxxxxx xxxxxxx (FGFs), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), insulinu podobný xxxxxxx xxxxxx-1 (XXX-1), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), xxxxxxx xxxxxx xxxxxxxx x krevních xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx růstový xxxxxx (XXXX), xxxxxx jako xxxxxxxxx xxxx růstové xxxxxxx xxxxxxxxxxx syntézu xxxx xxxxxxxxx bílkovin xxxxx, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových xxxxxx;
x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.
X3. XXXX2- AGONISTÉ
Xxxxxxx xxxx-2 xxxxxxxx (xxxxxx xxxx případných xxxxxxxxx xxxxxxx) xxxx xxxxxxxx xxxxx salbutamolu (maximálně 1600 xxxxxxxxxx xx 24 hodin), xxxxxxxxxxx (xxxxxxxxx 36 xxxxxxxxxx xx 24 xxxxx) x salmeterolu xxxxx xxxx xxxxxx x xxxxxxxx x xxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx.
Přítomnost xxxxxxxxxxx v xxxx x xxxxxxxxxxx xxxxx xxx 1000 ng/ml x přítomnost formoterolu x moči v xxxxxxxxxxx xxxxx než 30 xx/xx xxxxxx xxxxxxxxxx xx zamýšlené xxxxxxxxxxxx použití, ale xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx sportovec xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou studií, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx dávky xxxxx xxx xxxx xxxxxxx maximum.
X4. XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Inhibitory xxxxxxxx, zahrnující:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx),xxxxxxxxx, formestan, xxxxxxxx, testolacton, xxx xx x xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:
Raloxifen, xxxxxxxxx, xxxxxxxxx, xxx xx x omezením xxxxx xx ně.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:
Xxxxxxxxxx, fulvestrant, xxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx včetně inhibitorů xxxxxxxxxx, ale xx x xxxxxxxx pouze xx xx.
5. Xxxxxxxxxxx xxxxxxxxxx: Xxxxxxxx xxxxx aktivovaný xxxxxxxxxxxxxx xxxxxxxxxxxxx /Peroxisome Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (PPARδ) agonists/ (xxxx. XX 1516) x Xxxxxxxx proteinkinasové xxx aktivované AMP x xxxxxxxxxxx x XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx xxxxxx (XXXX) xxxx xxxxxxxx/ (xxxx. XXXXX)
X5. XXXXXXXXX X XXXXXXX XXXXXXXXX XXXXX
Maskovací xxxxx xxxx xxxxxxxx. Xxxxxxxx:
Xxxxxxxxx, desmopressin, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx albuminu, dextranu, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx x další xxxxx s xxxxxxxxx xxxxxxxxxxxx účinky. Xxxxxxx xxxxxxxx felypressinu pro xxxxx xxxxxxxx není xxxxxxxx.
Xxxxxxxxx xxxxxxxx:
Xxxxxxxxxxxx, amilorid, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, spironolakton, thiazidy (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (kromě xxxxxxxxxxxx, xxxxxxxxx x lokálního xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, které xxxxxx xxxxxxxx).
Pro xxxxxxx (Xxx Xxxxxxx, xxxxxxxx Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx látky xx xxxxxxxxxx prahovým xxxxxxx (xx. formoterol, xxxxxxxxxx, xxxxxx, katin, xxxxxxx, xxxxxxxxxxxx a xxxxxxxxxxxxx) xx xxxxxxx x xxxxxxxxxx nebo xxxxx xxxxxxxxx látkou je xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx xx xxxx xxxxx xxxxx x té, xxxxx xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.
XXXXXXXX XXXXXX
X1. XXXXXXXXX XXXXXXX KYSLÍKU
Xxxxxxxx je xxxxxxxxxxx:
1. Xxxxxx doping, xxxxxx xxxxxxx xxxxxxxxx, xxxxxxxxx xxxx heterologní xxxx xxxx červených xxxxxxx a xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx.
2. Umělé xxxxxxxxx xxxxxxxx, přenosu xxxx xxxxxxx xxxxxxx, xxxxxxxxxx xxxxxxxxxxxx hemoglobinové xxxxxxxx (např.krevní xxxxxxxx xxxxxxxx xx hemoglobinu, xxxxxxxxxxxxxxxxxx hemoglobiny), perfluorochemikálie x xxxxxxxxxxx (XXX13), xxx xx x xxxxxxxx xxxxx xx xx. Xxxxxxxx kyslíku xxxxxxxx není.
X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
1. Podvádění, xxxx xxxxx x xxxxxx, xx xxxxxx xxxxxxx integritu x xxxxxxxx Xxxxxx odebraných xxx Xxxxxxxxx xxxxxxxx xx xxxxxxxx. To xxxxxxxx xxxxxx a/nebo xxxxxx (xxxx. xxxxxxxxxx) xxxx, ale xx x xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx více xxx 50 xx xx 6 hodin xxxx xxxxxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx nemocničních xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.
3. Postupný xxxxx, xxxxxxxxxx x xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxx krve do xxxxxxxxx systému xx xxxxxxxx.
X3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:
1. Xxxxxxxx xxxxxxxxxx kyselin xxxx xxxxxx sekvencí;
2. Použití xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;
XXXXX X METODY XXXXXXXX XXX XXXXXXX |
Xxxxx kategorií XX xx X5 x X1 xx M3 xxxxxxxxx xxxx xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx skupiny:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Xxxxxxx stimulancia (xxxxxx xxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx) xxxx xxxxxxxx, s xxxxxxxx xxxxxxxx xxxxxxxxx x xxxxxxx jejich xxxxxxxx použití x xxxxxxxxxxx xxxxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2012*.
Stimulancia xxxxxxxx:
(x) Nespecifická xxxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxx, ethylamfetamin, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, kropropamid, krotetamid, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, modafinil, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx.
Xxxxxxxxxxxx, xxxxx není xxxxxxxx xxxxxxx v xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.
(b) Xxxxxxxxxx xxxxxxxxxxx (příklady):
Xxxxxxxxx**, xxxxx***, efedrin****, xxxxxxxx, etilefrin, xxxxxxxxxxx, xxxxxxxxxxx, fenprometamin, xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx****, xxxxxxxxxxxxx, methylhexanamin (xxxxxxxxxxxxxxxxx), niketamid, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, propylhexedrin, xxxxxxxxxxxxx*****xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx a xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
* Následující xxxxx xxxxxxxx xx Monitorovacího xxxxxxxx 2012 (bupropion, xxxxxxxxxx, fenylpropanolamin, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) xxxxxx xxxxxxxxxx xx Xxxxxxxx látky.
** Xxxxxxx xxxxxx adrenalinu (xxxx. nosní, xxxx xxxxxxxx) nebo xxxx xxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.
*** Xxxxx xx xxxxxxxx xxxxx xxx koncentraci xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.
**** Xxxxxxx x methylefedrin xxxx xxxxxxxx při xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx x 1 xx moči.
***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx xxxx koncentrace x moči xx xxxxx xxx 150 xxxxxxxxxx xx xxxxxxxx
X7. XXXXXXXXX
Zakázané xx xxxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x xxxx deriváty, xxxxxxxxxxx, metadon, morfin, xxxxxxxx, xxxxxxxxx, pentazocin, xxxxxxx.
S8. XXXXXXXXXXX
Xxxxxxxx (xxxx. xxxxx, xxxxxx x marihuana) xxxx xxxxxxxxxx xxxxx9xxxxxxxxxxxxxxxxxxx (XXX) a xxxxxxxxxxxxxx (xxxx. "Xxxxx" /obsahující XXX018, XXX073/ x XX-210) xxxx zakázané.
X9. XXXXXXXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.
XXXXX XXXXXXXX X XXXXXXXX XXXXXXXX |
X1. XXXXXXX
Alkohol (etanol) xx xxxxxxxx pouze Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx bude provádět xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx xxxx. Xxxxxxx xxxxxxx pro porušeni xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) xx 0.10 x/x.
∙ Xxxxxxxxxxxx xxxxx (FIA)
∙ Xxxxxx (WKF)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (XXXX)
∙ Xxxxxxxxxxx xxxxx (FIM)
∙ Xxxxx xxxxxxxxxx (XXX)
X2. XXXX-XXXXXXXXX
Xxxxx xxxx jinak xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Při Xxxxxxx x následujících xxxxxxxx.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
∙ Xxxxx (XXX)
∙ Xxxx (XXX)
∙ Xxxxxxx x xxxxxxx (XXX)
∙ Xxxxxxx sporty x xxxxxxxxxxxx (XXX)
∙ Xxxxxxxxxxx (FITA, IPC) (xxxxxxxx xxxx Mimo xxxxxx)
∙ Xxxxxxxx (XXX) - skoky xx xxxxxx x xxxxxxxxxxx lyžování-skoky x X-xxxxx,x snowboard U-rampa x "xxx air"
∙ Petanque a xxxxxxx sporty (XXXX)
∙ Střelba (XXXX, XXX) (xxxxxxxx také Xxxx soutěž)
∙ Xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (UlM)
Xxxx-xxxxxxxxx xxxxxxxx následující xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, betaxolol, bisoprolol, xxxxxxx, celiprolol, esmolol, xxxxxxxxx, karvedilol, xxxxxxxxx, xxxxxxxxxxx, metipranolol, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx xx x xxxxxxxx xxxxx na xx.
Informace
Xxxxxx xxxxxxx x. 97/2012 Xx. m. x. xxxxx xxxxxxxxx xxxx 25.12.2012.
Xxxxxx xxxxxxx x. 97/2012 Xx. m. x. byl xxxxxx xxxxxxx xxxxxxxxx č. 98/2013 Sb. m. s. x xxxxxxxxx od 20.12.2013.
Xxxxx xxxxxxxxxxxx právních xxxxx xxxxxx právních xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx.